Banque Pictet & Cie’s Allogene Therapeutics ALLO Stock Holding History

Banque Pictet & Cie’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-82,137	Closed	-$1.23M	–	622
2021 Q4	$1.23M	Buy	+82,137	New	+$1.45M	0.01%	434

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Banque Pictet & Cie's ALLO Position: Q1 2022 in Review

Banque Pictet & Cie sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 82,137 shares — an estimated $1.23M sold.

Banque Pictet & Cie first reported a position in ALLO in Q4 2021 and held it in 1 quarter. The position peaked at $1.23M in Q4 2021. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

Banque Pictet & Cie reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
Banque Pictet & Cie sold 82,137 Allogene Therapeutics shares in Q1 2022, an estimated $1.23M.
Banque Pictet & Cie first reported a position in Allogene Therapeutics in Q4 2021 and held it in 1 quarter.
Banque Pictet & Cie's Allogene Therapeutics position peaked at $1.23M in Q4 2021.
180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Banque Pictet & Cie's 13F filing for Q1 2022, filed 4 May 2022.